Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model

Journal of Cardiology

Volumn 59, Issue 1, 2012, Pages 91-96

  Sohma, Ryoichi ^a,b   Inoue, Teruo ^b   Abe, Shichiro ^b   Taguchi, Isao ^b   Kikuchi, Migaku ^b   Toyoda, Shigeru ^b   Arikawa, Takuo ^b   Hikichi, Yutaka ^a   Sanada, Shoji ^c   Asanuma, Hiroshi ^d   Kitakaze, Masafumi ^e   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Angiotensin receptor blocker; Left ventricular systolic function; Myocardial infarction; Statin

Indexed keywords

LOSARTAN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY LIGATION; DIASTOLIC BLOOD PRESSURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTION; HEART PROTECTION; HEART RATE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART WEIGHT; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOW DRUG DOSE; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; CARDIOTONIC AGENTS; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEMODYNAMICS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOSARTAN; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 84855197049     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.07.013     Document Type: Article

References (19)

1. Yasunari K., Maeda K., Watanabe T., Nakamura M., Yoshikawa J., Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004, 43:2116-2123.
2. Yusuf S. From the HOPE to the ONTARGET and TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002, 89:18A-25A.
3. Gould A.L., Davies G.M., Alemao E., Yin D.D., Cook J.R. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther 2007, 29:778-794.
4. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
5. Inoue T., Node K. Statin therapy for vascular failure. Cardiovasc Drugs Ther 2007, 21:281-295.
6. Kitakaze M., Asanuma H., Funaya H., Node K., Takashima S., Sanada S., Asakura M., Ogita H., Kim J., Hori M. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine myocardial ischemia. J Am Coll Cardiol 2002, 40:162-166.
7. Weber K.T. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997, 96:4065-4082.
8. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000, 101:2981-2988.
9. Szarszoi O., Mary J., Ostradal P., Netuka I., Besik J., Kolar F., Ostadal B. Effect of acute and chronic simvastatin treatment on post-ischemic contractile dysfunction in isolated rat heart. Physiol Res 2008, 57:793-796.
10. Tiefenbacher C.P., Kapitza J., Dietz V., Lee C.H., Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol 2003, 285:H59-H64.
11. Wayman N.S., Ellis B.L., Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Med Sci Monit 2003, 9:BR155-BR159.
12. Bao N., Ushikoshi H., Kobayashi H., Yasuda S., Kawamura I., Iwasa M., Yamaki T., Sumi S., Nagashima K., Aoyama T., Kawasaki M., Nishigaki K., Takemura G., Minatoguchi S. Simvastatin reduces myocardial infarct size via increased nitric oxide production in normocholesterolemic rabbits. J Cardiol 2009, 53:102-107.
13. Sanada S., Asanuma H., Minamino T., Node K., Takashima S., Okuda H., Shinozaki Y., Ogai A., Fujita M., Hirata A., Kim J., Asano Y., Mori H., Tomioke H., Kitamura S., et al. Optical windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3 kinase. Circulation 2004, 110:2143-2149.
14. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., Goldberg A.T., Zellner J.L., Crumbley A.J. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102:1944-1949.
15. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., Shiomi M., Schoen F.J., Libby P. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001, 103:276-283.
16. Node K., Fujita M., Kitakaze M., Hori M., Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839-843.
17. Teshima Y., Yufu K., Akioka H., Iwao T., Anan F., Nakagawa M., Yonemochi H., Takahashi N., Hara M., Saikawa T. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction. J Cardiol 2009, 53:58-64.
18. Lee T., Lin M., Chou T., Chang N. Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infracted rats. Am J Physiol Heart Circ Physiol 2006, 291:H1281-H1289.
19. Yamamoto E., Yamashita T., Tanaka T., Kataoka K., Tokutomi Y., Lai Z., Dong Y., Matsuba S., Ogawa H., Kim-Mitsuyama S. Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol 2007, 27:556-563.